Annette Langer-Gould
Overview
Explore the profile of Annette Langer-Gould including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
4277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schoeps V, Smith J, Langer-Gould A
Mult Scler
. 2025 Feb;
:13524585251318293.
PMID: 39968872
Background: Multiple studies identified an association between migraines and multiple sclerosis (MS). Objective: To investigate whether migraines increase MS risk or are part of the MS prodrome. Methods: Incident MS...
2.
Androdias G, Lunemann J, Maillart E, Amato M, Audoin B, Bruijstens A, et al.
Brain
. 2024 Dec;
PMID: 39707906
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs...
3.
Langer-Gould A
Mult Scler
. 2024 Dec;
30(5_suppl):9-11.
PMID: 39658899
Multiple sclerosis (MS) susceptibility and prognosis vary by race and ethnicity in the USA. MS incidence is highest in Black individuals and, among individuals under the age of 35, so...
4.
Dunlop E, Daly A, Mori T, Langer-Gould A, Pereira G, Black L
Mult Scler Relat Disord
. 2024 Oct;
92:105920.
PMID: 39406153
Background: There are plausible mechanisms, yet mixed evidence, that higher polyunsaturated fatty acids (PUFAs) levels reduces the risk of multiple sclerosis (MS). Prior studies relied on dietary surveys to estimate...
5.
Bernstein Sideman A, Nguyen H, Langer-Gould A, Lee E, Borson S, Shen E, et al.
BMC Prim Care
. 2024 Aug;
25(1):286.
PMID: 39107706
Background: Cognitive impairment and dementia are frequently under-recognized. Health system strategies anchored in primary care are essential to address gaps in timely, comprehensive diagnosis. The goal of this paper is...
6.
Piehl F, Alping P, Virtanen S, Englund S, Burman J, Fink K, et al.
Ann Neurol
. 2024 Jun;
96(4):678-693.
PMID: 38923558
Objective: To assess comparative effectiveness, safety, and tolerability of off-label rituximab, compared with frequently used therapies approved for multiple sclerosis (MS). Methods: A Swedish cohort study of persons with relapsing-remitting...
7.
Alsalek S, Schwarzmann K, Budhathoki S, Hernandez-Lopez V, Smith J, Li B, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 May;
11(4):e200255.
PMID: 38728608
Objectives: To estimate the incidence of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis. Methods: We conducted a retrospective cohort study of >10 million person-years of observation from members of Kaiser Permanente Southern California,...
8.
Akinsanya J, Smith J, Langer-Gould A
Mult Scler Relat Disord
. 2024 Apr;
86:105577.
PMID: 38579569
We sought to determine whether a history of traumatic brain injury (TBI) could explain the lower symbol digit modalities test (SDMT) scores observed among newly diagnosed multiple sclerosis (MS) and...
9.
Langer-Gould A, Li B, Smith J, Xu S
Neurol Neuroimmunol Neuroinflamm
. 2024 Mar;
11(3):e200211.
PMID: 38507657
Background And Objectives: B-cell-depleting therapies increase the risk of infections and hypogammaglobulinemia. These relationships are poorly understood. The objectives of these analyses were to estimate how much of this rituximab-associated...
10.
Langer-Gould A, Igbinosa I
Neurology
. 2024 Jan;
102(4):e209207.
PMID: 38261992
No abstract available.